Recombinant Human Gastric inhibitory polypeptide receptor (GIPR)

What is the basic structure of human GIPR?

Human Gastric Inhibitory Polypeptide Receptor (GIPR) is a transmembrane G protein-coupled receptor primarily expressed in pancreatic beta-cells. Structurally, GIPR consists of a 117 amino acid extracellular domain (ECD) at its N-terminus, a central region with seven transmembrane domains, and a 68 amino acid C-terminal cytoplasmic domain responsible for intracellular signal transduction via G-protein coupling. The receptor has three known isoforms produced through alternative splicing mechanisms. The extracellular domain of human GIPR shares 76.3% and 81.2% amino acid identity with mouse and rat homologs, respectively, which is important to consider when conducting cross-species research .

How does GIPR function in normal physiology?

While GIPR was initially thought to primarily inhibit gastrin and gastric acid secretion (hence its name), subsequent research has established that its principal physiological function is stimulating insulin release in response to elevated blood glucose levels. GIPR binds to its endogenous ligand, glucose-dependent insulinotropic polypeptide (GIP), triggering a signaling cascade that ultimately results in insulin secretion from pancreatic beta cells. Beyond insulin regulation, GIPR signaling has been implicated in bone health and density maintenance. Studies in mouse models show that overexpression of GIP and GIPR increases osteoblast levels and decreases age-related bone loss, while GIPR knockout mice exhibit decreased bone mass and compromised bone integrity .

What is the molecular basis for GIPR ligand recognition?

The cryo-electron microscopy structure of human GIPR in complex with GIP and a G protein heterotrimer, resolved at 2.9 Å, has provided crucial insights into ligand recognition mechanisms. GIP adopts a single straight helix conformation when bound to GIPR, with its N-terminus inserting into the receptor's transmembrane domain (TMD) pocket. Meanwhile, the C-terminus of GIP associates closely with the extracellular domain and extracellular loop 1 of the receptor. GIPR employs a dual recognition strategy: conserved residues in the lower half of the TMD pocket recognize common segments shared by GIP homologous peptides, while non-conserved residues in the upper half interact with GIP-specific residues. This structural arrangement provides the molecular basis for the ligand selectivity observed with GIPR, explaining why GIP does not bind to other class B1 GPCRs .

What are the validated methods for assessing GIPR binding activity?

Several robust methodologies have been established for evaluating GIPR binding activity. One validated approach involves using streptavidin-coated plates to capture biotinylated human GIP peptide, followed by assessment of its binding to recombinant human GIPR Fc chimera protein. In such binding assays, the ED50 typically ranges from 20.0-100 ng/mL, providing a quantifiable metric of binding affinity. Another established method uses radiolabeled ligands such as 125I-labeled GIP analogs in competitive binding assays. For this approach, cells expressing GIPR are seeded in poly-d-lysine coated plates, then incubated with a mixture of radiolabeled GIP (approximately 60 pM) and serial dilutions of test compounds. This methodology allows for precise determination of binding constants and competitive inhibition profiles for potential GIPR modulators .

How can researchers reliably measure GIPR-mediated signaling in cellular models?

Researchers typically employ cAMP accumulation assays as the gold standard for measuring GIPR-mediated signaling, since GIPR primarily couples to Gαs proteins that stimulate adenylyl cyclase and subsequent cAMP production. Established protocols involve transiently or stably expressing wild-type or mutated GIPR in HEK 293T cells, treating with GIP or other ligands of interest, and measuring intracellular cAMP levels. Results are typically normalized to the maximum response of wild-type receptors, and dose-response curves are analyzed using three-parameter logistic equations. For reliable data, experiments should be conducted in at least triplicate with quadruplicate technical replicates. This methodology has been successfully employed to characterize signaling profiles of various GIPR mutants, providing insights into structure-function relationships of receptor activation .

What methods are effective for recombinant GIPR protein characterization?

For proper characterization of recombinant GIPR proteins, a multi-method approach is recommended. SDS-PAGE analysis under both reducing and non-reducing conditions provides information about protein purity and potential oligomerization states. For instance, recombinant human GIPR Fc chimera protein typically shows bands at 45-59 kDa under reducing conditions and 90-120 kDa under non-reducing conditions when visualized by Coomassie Blue staining. Functional validation through binding assays with known ligands is essential to confirm proper folding and activity. Additionally, mass spectrometry analysis can verify protein integrity and post-translational modifications. For glycosylated recombinant GIPR preparations, enzymatic deglycosylation followed by size analysis can provide insights into the contribution of glycosylation to the observed molecular weight .

How can structure-activity relationship studies be designed for GIPR peptide antagonists?

Structure-activity relationship (SAR) studies for GIPR peptide antagonists require systematic modification of peptide sequences derived from human or mouse GIP, often combined with fatty acid-based protraction for extended half-life. A comprehensive approach involves:

• Sequence modification: Systematic alteration of key residues, particularly focusing on N-terminal truncations (positions 3-30, 5-30, 6-30) that have demonstrated antagonistic properties

• Binding affinity assessment: Competitive binding assays against radiolabeled GIP

• Functional antagonism testing: cAMP accumulation assays in GIPR-expressing cells with varying concentrations of antagonist in the presence of a fixed EC80 concentration of native GIP

• Specificity profiling: Cross-reactivity testing against related receptors, particularly GLP-1R

• Pharmacokinetic optimization: Addition of fatty acid modifications to improve half-life

This methodological framework has proven successful in developing potent, specific GIPR antagonists that effectively block GIP action across in vitro systems, ex vivo human islets, and in vivo mouse models .

What experimental designs effectively evaluate GIPR's role in diabetes and obesity?

Rigorous experimental designs for evaluating GIPR's role in metabolic disorders should employ complementary in vitro, ex vivo, and in vivo approaches. For in vitro assessment, dose-response curves of GIPR agonists or antagonists in receptor-expressing cell lines provide foundational data on signaling efficacy. Ex vivo studies using islets isolated from human donors offer translational insights into species-specific responses, which is particularly important given known differences between rodent and human GIPR pharmacology. For in vivo studies, diet-induced obesity (DIO) mouse models treated with GIPR modulators (alone or in combination with GLP-1R agonists) with comprehensive metabolic phenotyping represent the gold standard. Key outcome measurements should include body weight trajectories, food intake, glucose tolerance, insulin sensitivity, energy expenditure, and changes in adipose tissue distribution. This multi-level experimental approach has successfully demonstrated that GIPR antagonism produces additive weight loss when combined with GLP-1R agonists in preclinical models .

How can researchers effectively study GIPR's connections with bone metabolism?

To investigate GIPR's role in bone metabolism, researchers should implement a multi-faceted approach combining genetic models, pharmacological interventions, and comprehensive bone phenotyping. Genetic approaches include GIPR knockout models and transgenic mice overexpressing GIP/GIPR specifically in bone cells. Pharmacological studies should employ long-acting GIPR agonists or antagonists administered to wild-type mice. Bone phenotyping should include:

These methodological approaches have revealed that mice overexpressing GIP and GIPR show increased osteoblast levels and decreased age-related bone loss, while GIPR knockout mice exhibit decreased bone mass and compromised bone integrity .

How should researchers interpret apparent contradictions in GIPR pharmacology literature?

The GIPR field contains several apparent contradictions, particularly regarding whether receptor agonism or antagonism is beneficial for treating obesity and diabetes. When faced with such contradictions, researchers should systematically evaluate:

• Species differences: Human and rodent GIPR can exhibit different pharmacological profiles. For example, some GIP fragments demonstrate variable profiles of antagonism and agonism in different species.

• Methodological variations: Different assay systems (cell lines, protein constructs, readouts) can yield divergent results. Compare experimental conditions carefully.

• Ligand-specific effects: Some reported "antagonists" (like hGIP(3-30)) may exhibit partial agonism at higher concentrations or in certain assay systems.

• Tissue-specific effects: GIPR signaling may have opposing effects in different tissues (pancreas vs. adipose tissue vs. bone).

• Context-dependent signaling: GIPR may produce different outcomes depending on metabolic status (normal vs. diabetic) or when co-activated with other receptors.

Current evidence suggests that GIPR antagonists can reduce weight in diet-induced obesity models, while dual GLP-1R/GIPR agonists have proven superior to GLP-1R monoagonists for weight reduction in clinical trials. These seemingly contradictory findings may reflect complex, tissue-specific roles of GIPR signaling .

What are the common technical challenges when working with recombinant GIPR and how can they be addressed?

Researchers working with recombinant GIPR frequently encounter several technical challenges:

• Protein expression and stabilization: GIPR expression and stabilization for structural studies has historically been difficult. Solution: Use of fusion proteins (such as Fc chimeras), expression in specialized insect cell systems, and addition of stabilizing agents during purification can improve yields.

• Variability in functional assays: cAMP accumulation assays sometimes show high inter-experiment variability. Solution: Include standard controls in each experiment, perform at least three independent experiments with quadruplicate technical replicates, and normalize data to maximum wild-type response.

• Specificity concerns: Some GIPR peptide fragments show cross-reactivity with GLP-1R or residual agonist activity. Solution: Comprehensive characterization across multiple receptor types and careful dose-response studies to identify any partial agonism.

• Inconclusive receptor dimerization results: Studies of GIPR homerization have yielded inconclusive results with techniques like BRET, FRET, and subcellular micropatterning. Solution: Employ multiple, complementary biophysical techniques and include appropriate positive and negative controls (such as β2-adrenoceptors for non-specific interactions) .

How should researchers interpret dose-response data for GIPR-targeting compounds?

Proper interpretation of dose-response data for GIPR-targeting compounds requires careful consideration of several factors:

• For agonists: Evaluate both potency (EC50) and efficacy (maximum response). Compare to reference compounds (like native GIP) tested in parallel. Consider measuring multiple signaling pathways, as some compounds may show biased signaling.

• For antagonists: Test across a range of concentrations against a fixed concentration (typically EC80) of the native ligand. Calculate IC50 values using appropriate software (e.g., GraphPad Prism) with nonlinear regression of log concentration vs. response. Be alert for partial agonism at higher concentrations.

• For binding data: Distinguish between binding affinity and functional effects. High binding affinity does not necessarily translate to potent functional effects.

• Statistical analysis: Use three-parameter logistic equations for standard sigmoidal curves. For complex data (like partial antagonism), more complex models may be required.

• Biological relevance: Consider how in vitro potencies relate to achievable concentrations in vivo. A compound with moderate potency but excellent pharmacokinetics may outperform a highly potent compound with poor stability .

What are the emerging applications of Targeted Radionuclide Therapy against GIPR-positive cancer cells?

Targeted Radionuclide Therapy (TRT) directed against GIPR-positive cancer cells represents an emerging frontier in oncology research. Studies have demonstrated that TRT targeting GIPR can induce significant cell cycle arrest, particularly at the G2 and M phases, accompanied by extensive DNA damage. This approach leverages the selective expression of GIPR in certain cancer types to deliver radioisotopes specifically to tumor cells. Researchers exploring this area should consider several methodological aspects:

• GIPR expression profiling: Comprehensive characterization of GIPR expression across cancer types using techniques like immunohistochemistry, western blotting, and qPCR

• Radiolabeled ligand development: Design of GIP analogues or anti-GIPR antibodies that maintain high binding affinity when conjugated to radioisotopes

• In vitro validation: Assessment of binding specificity, internalization kinetics, and cytotoxic effects in GIPR-positive vs. GIPR-negative cell lines

• In vivo biodistribution: Evaluation of tumor targeting vs. normal tissue uptake using appropriate animal models

This therapeutic approach may be particularly valuable for cancers resistant to conventional treatments, offering a novel strategy for targeted cancer therapy based on GIPR biology .

How do structural insights inform the design of selective GIPR modulators?

The high-resolution (2.9 Å) cryo-EM structure of human GIPR in complex with GIP and a G protein heterotrimer has provided crucial insights for rational drug design. This structure reveals that GIP adopts a single straight helix conformation with its N-terminus inserted into the receptor's transmembrane domain pocket and its C-terminus associating with the extracellular domain and extracellular loop 1.

For structure-based design of selective GIPR modulators, researchers should focus on:

• The differential use of conserved vs. non-conserved residues in the TMD binding pocket: GIPR employs conserved residues in the lower half of the pocket to recognize common segments of GIP-related peptides, while using non-conserved residues in the upper half to interact with GIP-specific residues

• Key interaction sites for antagonist development: Focusing on the N-terminal region of GIP and its specific receptor interactions, as GIP fragments lacking the N-terminal region (e.g., GIP(3-30)) can function as antagonists

• Structure-guided mutagenesis: Systematic mutation of residues in the binding pocket can validate their importance and guide optimization of selective compounds

• Molecular dynamics simulations: Computational methods can explore conformational changes and binding energetics beyond the static crystal structure

This structural framework provides a foundation for developing highly selective GIPR modulators with optimized pharmacological profiles for potential therapeutic applications in metabolic disorders .